Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

IV antibiotics

- PMLiVE

WHO releases 13 interventions to help address antimicrobial resistance

The organisation has declared AMR as one of the top ten threats to global public health

- PMLiVE

Life sciences leaders warn against ‘unworkable’ changes to UK medicines scheme

The scheme could impact UK life sciences and NHS patient access to medicines

- PMLiVE

Sanofi enters agreement with Janssen to develop E. coli vaccine candidate

Extraintestinal pathogenic E. coli is a leading cause of sepsis, particularly in older adults

- PMLiVE

NHS expands diagnostic capabilities to reform cancer standards for patients

Thousands of patients are set to receive faster diagnosis and treatment

- PMLiVE

UK government invests £210m to fight antimicrobial resistance

The investment is the largest by a single country in global AMR surveillance

- PMLiVE

NHS achieves new record for cancer checks for patients

Nearly three million patients have had cancer checks by the NHS in the last year

- PMLiVE

NHS to initiate flu vaccine roll-outs for children from September

The roll-outs are part of the NHS winter flu and COVID-19 vaccination programme

- PMLiVE

New NHS treatments increase survival rates for babies with spinal muscular atrophy

Around 70 babies are born with the rare muscle-wasting disease each year in the UK

Can Cinderella save us?

New study finds vaccines could avert 500,000 antimicrobial resistance deaths each year

AMR has been declared by WHO as one of the top ten threats to global public health

- PMLiVE

NHS extends eligibility for shingles vaccine to almost one million people

Approximately one in four people will develop shingles and the risk increases with age

- PMLiVE

NHS launches plans to expand drug contracts to develop new life-saving antibiotics

New antibiotics could reduce death rates and ensure future pandemic preparedness

- PMLiVE

Shionogi to acquire Qpex Biopharma for approximately $140m

The deal signifies a notable expansion to the Japanese drugmaker’s antimicrobial pipeline

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links